Israel’s Teva and Sanofi announced promising Phase 2 trial results for duvakitug, designed to treat colitis and Crohn’s disease. In a 14-week phase 2b multi-national study, nearly 50% of patients achieved clinical remission compared with around 20% on a placebo. … Continue reading →

Israel’s Teva is partnering with France’s Sanofi (see also here) to develop and commercialize TEV 574, currently in Phase 2b clinical trials, for the anti-TL1A treatment of ulcerative colitis and Crohn’s Disease, two types of inflammatory bowel disease (IBD). https://en.globes.co.il/en/article-teva-teams-with-sanofi-on-inflammatory-bowel-treatment-1001459330

Israel’s CytoReason (see here previously) is partnering France’s Sanofi to identify novel therapies to treat Inflammatory Bowel Disease (IBD). Sanofi will pay CytoReason millions of dollars to use the Israeli startup’s computational AI-discovery disease model platform. https://www.timesofisrael.com/sanofi-extends-cooperation-with-israels-cytoreason-for-bowel-disease-drug-discovery/